Stocks · News reference
AEON Biopharma Announces Final, Expanded Primary Structure Results And Preliminary Disulfide Bond Characterization Data Providing Complementary Evidence Supporting Molecular Similarity Of ABP-450 To BOTOX
- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed - Preliminary
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why AeroVironment Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
AeroVironment surged 5.8% premarket after beating Q1 revenue and EPS estimates; Synergy CHC led gainers, while Ribbon Acquisition fell.
AEON Biopharma Says Pilot Forced Degradation Study Showed ABP-450 And AbbVie's BOTOX Lost Potency At Comparable Rates Under Thermal Stress, Similar Methionine Oxidation Patterns; Plans Multi-Lot Comparability Study In H1 2027
AEON Biopharma Designates Paul Lee As Chief Regulatory Office